Mumbo Jumbo, confusingIventuret seems CRH has become a hub of the unemployd executives these days adding to overhead without increasing the bottom line. In any case, I looked over the teleconference and I am still puzzled with the mumbo jumbo rhetoric of these officials, Could someone please put some meat on these bones so we can make some sense of this jargon? Here is what they said about the Di Novo business as a new tactic to increase business:with respect to business development, during the fourth quarter of 2019, we doubled the size of our business development team. In addition to expanding this BD team, we also expanded a variety of approaches that we can use to engage with prospective targets. We envision growing our anesthesia business now through a portfolio approach with a mix of de novo deals, coupled with more traditional capital deployment-related transactions. We view these de novos as an attractive means of development as they tend to be a cashless, sweat equity means of entry into a market. Anybody understands what a "Di Novo" deal is? Monty, what is your take? Thanks